REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of Form 8-K

MaxCyteAnnouncement

29/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240129:nRSc1340Ba&default-theme=true

RNS Number : 1340B  MaxCyte, Inc.  29 January 2024

 

 

 

MaxCyte announces filing of Form 8-K

 

ROCKVILLE, MD, January 29, 2024 - MaxCyte, Inc. (https://maxcyte.com/) ,
(Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, announces that it has filed a Form 8-K
with the SEC announcing the departure of Dr. Cenk Sumen as Chief Scientific
Officer. Dr. Sumen will maintain a relationship with the Company as a member
of MaxCyte's Scientific Advisory Board.

 

A copy of the Form 8-K is available to view on the SEC's website at
www.sec.gov (http://www.sec.gov) and has also been posted to the "SEC filings"
page of the Company's website, https://investors.maxcyte.com/
(https://investors.maxcyte.com/) .

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more at
maxcyte.com (https://maxcyte.com/) and follow us on X
(https://twitter.com/MaxCyte_info) (formerly Twitter) and LinkedIn
(https://www.linkedin.com/company/maxcyte-inc-/) .

 

MaxCyte Contacts:

 

 US IR Adviser                                   +1 415-937-5400

 Gilmartin Group                                 ir@maxcyte.com (mailto:ir@maxcyte.com)

 David Deuchler, CFA
 Nominated Adviser and Joint Corporate Broker

 Panmure Gordon                                  +44 (0)20 7886 2500

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser

 ICR Consilium                                   +44 (0)203 709 5700

 Mary-Jane Elliott                               maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 Chris Welsh

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUWARRSAUAUUR